Involvement of human release factors eRF3a and eRF3b in translation termination and regulation of the termination complex formation

被引:65
作者
Chauvin, C
Salhi, S
Le Goff, C
Viranaicken, W
Diop, D
Jean-Jean, O
机构
[1] Univ Paris 06, CNRS, UMR 7098, Unite Biochim Cellulaire, F-75252 Paris, France
[2] Univ Rennes 1, CNRS, UMR 6061, IFR 140 GFAS, F-35043 Rennes, France
[3] Univ Cheick Anta Diop, Fac Med & Pharm, Dakar, Senegal
关键词
D O I
10.1128/MCB.25.14.5801-5811.2005
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
eRF3 is a GTPase associated with eRF1 in a complex that mediates translation termination in eukaryotes. In mammals, two genes encode two distinct forms of eRF3, eRF3a and eRF3b, which differ in their N-terminal domains. Both bind eRF1 and stimulate its release activity in vitro. However, whether both proteins can function as termination factors in vivo has not been determined. In this study, we used short interfering RNAs to examine the effect of eRF3a and eRF3b depletion on translation termination efficiency in human cells. By measuring the readthrough at a premature nonsense codon in a reporter mRNA, we found that eRF3a silencing induced an important increase in readthrough whereas eRF3b silencing had no significant effect. We also found that eRF3a depletion reduced the intracellular level of eRF1 protein by affecting its stability. In addition, we showed that eRF3b overexpression alleviated the effect of eFX3a silencing on readthrough and on eRF1 cellular levels. These results suggest that eRF3a is the major factor acting in translation termination in mammals and clearly demonstrate that eRF3b can substitute for eRF3a in this function. Finally, our data indicate that the expression level of eRF3a controls the formation of the termination complex by modulating eRF1 protein stability.
引用
收藏
页码:5801 / 5811
页数:11
相关论文
共 40 条
[21]  
JeanJean O, 1996, CR ACAD SCI III-VIE, V319, P487
[22]   The GTP-binding release factor eRF3 as a key mediator coupling translation termination to mRNA decay [J].
Kobayashi, T ;
Funakoshi, Y ;
Hoshino, S ;
Katada, T .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (44) :45693-45700
[23]   Crystal structure and functional analysis of the eukaryotic class II release factor eRF3 from S. pombe [J].
Kong, CG ;
Ito, K ;
Walsh, MA ;
Wada, M ;
Liu, YY ;
Kumar, S ;
Barford, D ;
Nakamura, Y ;
Song, HW .
MOLECULAR CELL, 2004, 14 (02) :233-245
[24]   Ilf3 and NF90 associate with the axonal targeting element of Tau mRNA [J].
Larcher, JC ;
Gasmi, L ;
Viranaïcken, W ;
Eddé, B ;
Bernard, R ;
Ginzburg, I ;
Denoulet, P .
FASEB JOURNAL, 2004, 18 (12) :1761-+
[25]   Mouse GSPT2, but not GSPT1, can substitute for yeast eRF3 in vivo [J].
Le Goff, C ;
Zemlyanko, O ;
Moskalenko, S ;
Berkova, N ;
Inge-Vechtomov, S ;
Philippe, M ;
Zhouravleva, G .
GENES TO CELLS, 2002, 7 (10) :1043-1057
[26]   Overexpression of human release factor 1 alone was an antisuppressor effect in human cells [J].
LeGoff, X ;
Philippe, M ;
JeanJean, O .
MOLECULAR AND CELLULAR BIOLOGY, 1997, 17 (06) :3164-3172
[27]  
Miccoli L, 1998, CANCER RES, V58, P5777
[28]  
Otto AI, 1999, CANCER RES, V59, P1212
[29]   Support for the prion hypothesis for inheritance of a phenotypic trait in yeast [J].
Patino, MM ;
Liu, JJ ;
Glover, JR ;
Lindquist, S .
SCIENCE, 1996, 273 (5275) :622-626
[30]   Interaction between yeast sup45p (eRF1) and sup35p (eRF3) polypeptide chain release factors: Implications for prion-dependent regulation [J].
Paushkin, SV ;
Kushnirov, VV ;
Smirnov, VN ;
TerAvanesyan, MD .
MOLECULAR AND CELLULAR BIOLOGY, 1997, 17 (05) :2798-2805